Current status of thalidomide in the treatment of cancer

ONCOLOGY

Volumn 15, Issue 7, 2001, Pages 867-874

  Rajkumar, S Vincent ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; THALIDOMIDE;

BLOOD DISEASE; CLINICAL TRIAL; HUMAN; MULTIPLE MYELOMA; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS; HEMATOLOGIC NEOPLASMS; HUMANS; MULTIPLE MYELOMA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THALIDOMIDE;

EID: 0035407607     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Lenz W: Thalidomide and congenital abnormalities. Lancet 1:45, 1962.
2. McBride WG: Thalidomide and congenital abnormalities. Lancer 2:1358, 1961.
3. Argiles JM, Carbo N, Lopez-Soriano FJ: Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? Med Hypotheses 50:313-318, 1998.
4. Parman T, Wiley MJ, Wells PG: Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5:582-585, 1999.
5. Iyer CG, Languillon J, Ramanujam K, et al: WHO coordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 45:719-732, 1971.